Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof;
• wherein
• m is 0, 1, 2, 3 or 4;
• 1Y and Y2 are independently N or CR8 provided that one of 1Y and Y2 is N and the other is CR8;
• X is a linker group selected from —CR4═CR5—, —CR4═CR5CR6R7—, —CR6R7CR5═CR4—, —C≡C—, —C≡CCR6R7—, —CR6R7C≡C—, —NR4CR6R7—, —OCR6R7—, —SCR6R7—, —S(O)CR6R7—, —S(O)2CR6R7—, —C(O)NR4CR6R7—, —NR4C(O)CR6R7—, —NR4C(O)NR5CR6R7—, —NR4S(O)2CR6R7—, —S(O)2NR4CR6R7—, —C(O)NR4—, —NR4C(O)—, —NR4C(O)NR5—, —S(O)2NR4— and —NR4S(O)2—;
• R1 is a group selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R9, —OR9, —SR9, —SOR9, —SO2R9, —COR9, —CO2R9, —CONR9R10, —NR9R10, —NR9COR10, —NR9CO2R10, —NR9CONR10R15, —NR9COCONR10R15 and —NR9SO2R10;
• R2 is
• wherein A1 and A2 are selected from CH or N provided that at least one of A1 or A2 is CH;
• each R3, when present, is independently selected from halo, cyano, nitro, —R13, —OR13, —SR13, —SOR13, —SO2R13, —COR13, —CO2R13, —CONR13R14,—NR13R14, —NR13COR14, —NR13CO2R14 and —NR13SO2R14;
• R4 and R5 are independently hydrogen or C1-6alkyl;
• or R1 and R4 together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1 -6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
• R6 and R7 are independently selected from hydrogen, halo, cyano, nitro and C1-6alkyl;
• R8 is selected from hydrogen, halo, cyano and C1-6alkyl;
• R9 and R10 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
• R13, R14, R15, and R19 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl.